BPG is committed to discovery and dissemination of knowledge
This Article
Academic Content and Language Evaluation of This Article
Citation of this article
Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101 [PMID: 25717243 DOI: 10.3748/wjg.v21.i7.2096]
Corresponding Author of This Article
Francois Ghiringhelli, MD, PhD, Department of Medical Oncology, Centre Georges-François Leclerc, INSERM Avenir 866, 1 rue du Professeur Marion, 21000 Dijon, France. fghiringhelli@cgfl.fr
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7694)
All Articles published online
|
Publishing Process of This Article
|
Feb 21, 2015 (publication date) through Nov 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Total Visits of This Article
2019 | Number of total visits
Rank | Countries/Territories | Count | Percent |
1 | 44 | 100% |